Therapeutic drug monitoring of albendazole: Determination of albendazole, albendazole sulfoxide, and albendazole sulfone in human plasma using nonaqueous capillary electrophoresis
A. Prochazkova et al., Therapeutic drug monitoring of albendazole: Determination of albendazole, albendazole sulfoxide, and albendazole sulfone in human plasma using nonaqueous capillary electrophoresis, ELECTROPHOR, 21(4), 2000, pp. 729-736
A nonaqueous capillary electrophoretic method (NACE) for the fast determina
tion of plasma levels of albendazole (ABZ), albendazole sulfoxide (ABZSO),
and albendazole sulfone (ABZSO(2)) is described. TI-le assay is based upon
liquid/liquid extraction of these compounds using dichloromethane at pH 10.
2 (recovery between 63 and 98%), followed by a NACE separation performed wi
thin 8 min employing a 0.036 M berate buffer (apparent pH 9.9) in a mixture
of methanol and N-methylfermamide (1:3) and on-column absorbance detection
at 280 nm. Using 0.5 mt of plasma and extract reconstitution in 200 mu L N
-methylformamide, drug levels between 1.0-10 mu M were found to provide lin
ear calibration graphs. Intraday and interday imprecisions evaluated from p
eak area ratios (n = 5) were < 10% and < 12%, respectively. Corresponding i
mprecisions of detection times (n = 5) were < 1% and < 6%, respectively. Th
e limit of detection (LOD) for ABZ, ABZSO and ABZSO(2) was 8 x 10(-7) M. Th
e reliability of the method developed was verified via analysis of 45 plasm
a samples obtained from patients treated with ABZ. Good agreement was obtai
ned between the levels of ABZSO and those determined by routine HPLC. ABZ w
as found to be undetectable in all patient samples, whereas the levels of A
BZSO(2) were below or close to LOD.